|
PLASMA TREATMENT TO ASYMPTOMATIC PATIENT WITH COVID-19 INFECTION |
|
Stem cells in patients with lung lesions (COVID-19) |
|
VIDA study |
|
Rectal Ozone in the COVID-19 treatment |
|
Biomodulina T - IM - covid-19 - older adult |
|
Heberon Alfa R in COVID-19 |
|
ATENEA-Co-300 study |
|
Exploratory study of BMT IM to stimulate immune response in patients with CKD-5 on iterated hemodialysis |
|
Evaluation of the synergistic effect of sequential administration of two immunostimulant products: Immuno-1 and Immuno-2 for the stimulation of the immune response in older adults. Exploratory study |
|
VA-MENGOC-BC to stimulate the innate response against SARS-CoV-2 |
|
CIGB-258 at COVID-19 |
|
PrevengHo-Vir Homeoprohylaxis COVID-2019 |
|
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab |
|
Biomodulina T - IM- covid-19 - older adultos - Phase IV clinical trial |
|
Therapy for COVID-19-Phase I-II |
|
Pharmacodynamics of the Nasalferon in healthy volunteers. |
|
ESPERANZA study |
|
CIGB 2020 in contacts and SARS-CoV-2 infection suspects |
|
EGF in bilateral symmetric diabetic neuropathy |
|
Enhanced recovery protocols in cardiac surgery protocols |
